WORLDWIDE HEALTHCARE TRUST ORD GBP0.25

Symbol: WWH

This security went ex-dividend on 22/11/2018. Pay date is 09/01/2019

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Past Performance

  • 15th Dec 2013 to 15th Dec 201438.09%
  • 15th Dec 2014 to 15th Dec 201510.48%
  • 15th Dec 2015 to 15th Dec 201612.76%
  • 15th Dec 2016 to 15th Dec 201725.00%
  • 15th Dec 2017 to 15th Dec 20184.38%

Key Information

Benchmark MSCI World/Health Care
Sector IT Biotechnology & Healthcare
AMC 0.65%
Total Ongoing Charges 
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing.
1.40%
Gearing 111%
Performance Fee No
Ex-Dividend Date 22 Nov 2018
Dividend Pay Date 9 Jan 2019
Total Dividends - Year to Date17.5
Dividend Yield (%)0.6679

Net Asset Value (Nav)

Latest actual NAV 2,606.85
Latest actual NAV date 12/12/2018
NAV frequency Daily
Premium/Discount 0.5%

Part of our Foundation Fundlist Part of our Foundation Fundlist
WHY IS THIS FUND ON OUR FOUNDATION FUNDLIST?

Company

Business Summary

Worldwide Healthcare Trust PLC is an investment trust. The Trust invests in the global healthcare sector with the objective of achieving a high level of capital growth. The Trust invests in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. The Trust uses gearing and derivative transactions. The Trust invests approximately 60% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. Its investment strategies also maintains that over 5% of the portfolio, at the time of acquisition, may be invested in each of debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over of 20% of the portfolio, at the time of acquisition, in companies under sectors, such as healthcare equipment and supplies, healthcare technology, and healthcare providers and services. OrbiMed Capital LLC is the portfolio manager of the Trust.

Financial Summary

BRIEF: For the six months ended 30 September 2018, Worldwide Healthcare Trust PLC revenues increased from £97.9M to £241.9M. Net income increased from £81.7M to £240.5M. Revenues reflect Gains on investments increase from £84.7M to £238.5M, Income from investments increase of 46% to £8.1M. Dividend per share remained flat at £0.07. Basic Earnings per Share excluding Extraordinary Items increased from £1.75 to £4.80.

Performance

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Cumulative Performance

      1 month3 months6 months1 year3 years5 years
      1.22% -6.69% -1.21% 4.38% 47.12% 124.46%

      Important Information
      Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertanly become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.

      The graphs shown are supplied by an external data provider and may contain data that appears to preced the introduction of the clean unit class for this fund. In such cases, historial data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.

      Composition

      Important Documents


      The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.

      Fund Provider Factsheet
      The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
      FUND PROVIDER FACTSHEET
      217,667 bytes PDF Document; last updated 31 Oct 2018
      Key Information Document This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
      KEY INFORMATION DOCUMENT
      274,835 bytes PDF Document; last updated 27 Sep 2018
      Annual Report A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
      ANNUAL REPORT
      2,502,975 bytes PDF Document; last updated 31 Mar 2018
      Semi Annual Report Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
      SEMI-ANNUAL REPORT
      4,209,206 bytes PDF Document; last updated 30 Sep 2018

      Management Team

      Trevor Polischuk Sven H Borho

      Trevor Polischuk has managed this fund for 0 months.

      Trevor Polischuk Trevor M. Polischuk, Ph.D., is a Public Equity Partner focused on the global pharmaceutical industry. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin. Dr. Polischuk holds a Doctorate in Neuropharmacology & Gross Human Anatomy from Queen's University and an M.B.A. from Queen's University.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Sven H Borho has managed this fund for 23 years and 7 months.

      Sven H Borho Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho is a senior member of the public equity team and he is a portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Mr. Borho studied business administration at Bayreuth University in Germany and received an M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      31/03/2013

      Total Revenue 50.85 264.24 -79.86 364.58 149.33 116.61
      Gross profit 29.62 250.24 -82.79 340.62 133.93 116.46
      Operating Profit/Loss 28.71 249.52 -83.55 339.80 133.18 113.36
      Profit Before Tax 28.71 249.52 -83.55 339.80 133.18 113.36
      Profit After Tax 27.18 248.37 -84.63 338.69 132.12 112.21
      Equity Holders of Parent Company 27.18 248.37 -84.63 338.69 132.12 112.21
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      31/03/2013

      Total Non-Current Assets 1,294.03 1,191.97 935.67 1,091.31 713.46 551.32
      Total Current Assets 17.12 17.84 20.84 11.78 25.31 11.45
      Total Assets 1,311.15 1,209.81 956.51 1,103.09 738.77 562.77
      Total Liabilities NIL NIL NIL NIL NIL NIL
      Total Net Assets NIL NIL NIL NIL NIL NIL
      Shareholders Funds 1,202.19 1,100.90 881.76 982.51 636.19 504.42
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity NIL NIL NIL NIL NIL NIL